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Abstract Life expectancy has increased by more than 30 years during the last century and continues to increase. Many women already
live decades in menopause deprived of naturally produced oestradiol and progesterone, leading to an increasing incidence of menopause-
related disorders such as osteoporosis, cardiovascular diseases and lack of general well-being. Exogenous oestradiol has tradition-
ally been used to alleviate menopause-related effects.
This commentary discusses a radical new method to postpone menopause. Part of the enormous surplus of ovarian follicles can
now be cryostored in youth for use after menopause. Excision of ovarian tissue will advance menopause marginally and will not reduce
natural fertility. Grafted tissue restores ovarian function with circulating concentrations of sex steroids for years in post-
menopausal cancer survivors. Future developments may further utilize the enormous store of ovarian follicles.
Currently, the main goal of ovarian cryopreservation is fertility preservation, but grafting of ovarian tissue may also serve endo-
crine functions as a physiological solution to prevent the massive medical legacy of osteoporosis and menopause-related conditions
in the ageing population. This intriguing solution is now technically available; the question is whether this method qualiﬁes for post-
poning menopause, perhaps initially for those patients who already have cryostored tissue?
© 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
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In parallel with increased ﬁnancial income and better way
of life now experienced in many parts of the world, in-
creased life expectancy follows. One century ago the average
age corresponding to the natural age of menopause was around
50 years, whereas nowadays the majority of women live
beyond 80 years in many countries. In fact, people over the
age of 85 years are the fastest growing population group in
the USA and people above 65 years will soon constitute more
than 20% of the population. Furthermore, a life expectancy
of more than 100 years has been estimated for half of all girls
born today in many western countries (Christensen et al.,
2009). Already now, many women spend around 30–40% of
their lives in menopause and face sequelae such as demin-
eralization of bones (i.e. osteoporosis), increased risk of
cardiovascular diseases and various cognitive disabilities, well-
being and sexuality (Lobo et al., 2014). Society is therefore
facing a considerable task in improving the quality of life and
longevity for senior women.
Already today menopause-related conditions involve major
medical interventions. Approximately one in two women over
the age of 50 years will suffer an osteoporosis-related frac-
ture in her remaining lifetime (review: de Vos et al., 2010,
www.osteo.org; www.nof.org). The cost of treating osteo-
porosis is fast increasing: in Canada it is estimated to rise from
Can$1.3 billion in 1993 to approximately Can$32.5 billion in
2018 (Goeree et al., 1996). In the USA the medical expense
for treating broken bones was estimated to be as high as $18
billion in 2006 (www.osteo.org, Ray et al., 1997).
http://dx.doi.org/10.1016/j.rbmo.2015.05.002
1472-6483/© 2015 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
Reproductive BioMedicine Online (2015) 31, 128–131
www.sciencedirect .com
www.rbmonl ine.com
Furthermore, many reports have demonstrated a link
between cardiovascular disease and women deprived of
oestrogens (de Vos et al., 2010). In a cohort of 12,000 post-
menopausal women it was shown that those who naturally
entered menopause early had a signiﬁcantly higher risk of car-
diovascular mortality than those who naturally entered meno-
pause later (de Vos et al., 2010). Therefore cardiovascular
disease in post-menopausal women represents a health hazard,
which negatively affects quality of life and well-being.
In parallel with the increased life expectancy the medical
and ﬁnancial burden for treating menopause-related condi-
tions will undoubtedly increase.
The ovary is the key organ in preventing these conditions
through its production of sex-steroids, most notably oestra-
diol and progesterone. The monthly selected follicle consti-
tutes the ‘sex-steroid producing factory of the ovary’ and
produces more than 90% of sex-hormones in each menstrual
cycle, exerting a myriad of effects in the body.
Traditionally menopausal effects have been tackled by
hormone replacement therapy (HRT), basically mimicking the
steroid output from the monthly pre-ovulatory follicle and the
accompanying corpus luteum. The HRT approach is well known
to have beneﬁcial effects on menopause-related symptoms,
but when the Women Health Initiative in California re-
ported an associated increased risk of breast cancer in 2002,
utilization of HRT plummeted (Lobo, 2014). Use of HRT is now
recovering after several studies have shown that HRT does
not increase, or only marginally increases, the risk of breast
cancer and cardiovascular disease (Lobo, 2014). Although
sooner or later women will become convinced of the new evi-
dence and start to use HRT again, the duration of HRT is often
limited only to the menopausal transition for a maximum of
4 to 5 years. The use of HRT for such a short period will only
postpone the onset of menopause-related symptoms, but for
women spending maybe 30 or more years in menopause there
is a considerable risk of experiencing related symptoms
anyway. The outlook to an osteoporosis epidemic has prompted
a recent paper to call for ‘new strategies for long-term os-
teoporosis prevention’ (Karim et al., 2011).
One such new strategy is available. Recent develop-
ments in the ability to freeze ovarian tissue now allow meno-
pause to be postponed. Ovarian tissue may be cryopreserved
in youth and then transplanted after menopause to provide
continued menstrual cycles. The method is used for fertility
preservation in women facing a potentially sterilizing
gonadotoxic treatment, developed almost two decades ago
(Hovatta et al., 1997; Picton and Gosden, 2000), but may also
be used for postponing menopause. This radical option makes
use of the enormous endogenous store of ovarian follicles that
otherwise normally undergo atresia (Figure 1A).
The ovaries of a newborn girl contain an average of one
million eggs, which are present in resting follicles. This ﬁnal
store is the exclusive source of eggs securing fertility andmen-
strual cycles after puberty until it become exhausted atmeno-
pause. Independent of age, some resting follicles will embark
on growth continuously but only one single follicle will be se-
lected each month for ovulation and provide the oocyte with
potential for new offspring. A woman will normally ovulate
around 450 times from puberty to menopause, whereas all
other follicles, representing 99.9%, will undergo degenera-
tion.Manyof the follicles constituting this enormous loss possess
the ability for growth and development and hence sex-steroid
secretion, but may not contain oocytes best suited for re-
production. In connectionwith assisted reproduction, it is well
known that many follicles possess the capacity to escape de-
generation and continue to grow and secrete sex hormones.
Furthermore, it is now well established that women with
one ovary remain as fertile as women with two ovaries (Lass
et al., 1997). A woman with one ovary will produce around
20% fewer mature oocytes compared with a woman with both
ovaries following ovarian stimulation, reﬂecting that fol-
licle atresia in the remaining ovary has become reduced and
more follicles will survive to the pre-ovulatory stage (Lass
et al., 1997). The age at menopause in normal women is only
marginally affected by having one ovary removed (Bjelland
et al., 2014; Yasui et al., 2012). Both studies found that women
with one ovary enter menopause around one year earlier than
women with two ovaries, illustrating the enormous surplus of
ovarian follicles. Basically normal women will experience little
if any effect on fertility and age of menopause by having
ovarian tissue removed when young.
It is nowwell established that cryopreservation of ovarian
tissuemaintains viable follicles that support fertility andmen-
strual cycles upon transplantation (Andersen et al., 2012a).
Current experience from our centre shows that tissue remains
active for surprisingly long periods (Andersen et al., 2012b).
In total, four patients had the ﬁrst tissue transplanted more
than 10 years ago in our centre. All have had a second (or in
one case three) transplantation performed since then. The
ﬁrst patient received all the tissue from one ovary through
three separate transplantations andmaintains ovarian activity
almost 11 years after the ﬁrst transplant. Another woman ex-
perienced ovarian activity for almost 7 years after having 55%
of one ovary transplanted. She is now in her forties with no
permanent partner and is not interested in having the re-
maining tissue transplanted for fertility purposes. The third
womanexperiencedovarianactivity for almost 6 years byhaving
all tissue transplanted. The tissue has now stopped functioning.
The last patient has had regularmenstrual cycles for 10.5 years
after having 62% of one ovary transplanted. The tissue is still
active and the patient has an opportunity to undergo one addi-
tional transplantation.Others also report on a prolongedperiod
of function fromtransplantedovarian tissue (Silber et al., 2015).
It is noticeable that tissue in these patients has been trans-
planted with the intention of providing fertility, which re-
quires a larger pool of follicles (i.e. more tissue) to be
transplanted than for providing menstrual cycles alone. There-
fore the longevity of this tissue if the aim was to postpone
menopause would probably be longer.
Follicular recruitment in transplanted tissue appears to
occur sequentially, often with regular menstrual cycles as in
a normal ovary. In normal women it has been shown that the
number of resting follicles recruited per month decreases
towards menopause while maintaining capacity to provide one
pre-ovulatory follicle per month (Wallace and Kelsey, 2010).
Therefore by removing ovarian tissue and cryostoring it, the
overall rate of follicular degeneration will be reduced. Fur-
thermore, ovarian cortical tissue from one ovary is usually
separated into around 25 pieces frozen in individual am-
poules. If the number of resting follicles recruited for growth
per month in each of these 25 pieces of ovarian cortex occurs
at a reduced rate as in peri-menopausal ovaries of normal
women (Wallace and Kelsey, 2010), grafting pieces one-by-
one may further expand the period with endogenous
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concentrations of sex steroids. In addition, ovarian tissue will
start to work in most places in the body and may be trans-
planted subcutaneously during local anaesthesia. In this way
natural fertility will be avoided and will prevent senior women
from becoming pregnant.
However, what risks and uncertainties are raised by this
newmethod for postponing menopause? Extended time periods
with menstrual cycles exceeding the age of natural men-
strual cycles may augment the risk of cancers such as breast
cancer. The alarm about the increased risk of breast cancer
caused by HRT that was raised 10 years ago has now changed,
and the current opinion is that little if any increase in the
breast cancer incidence can be ascribed to the use of HRT
(Lobo, 2014). However, this may not apply to all women, and
how will prolonged ovarian function affect the breast cancer
risk and that of other types of cancer such as cervical cancer?
Careful consideration, individually tailored advice and close
monitoring are needed for women who may want to use their
ovarian tissue for postponing menopause.
Although many women will not want to continue having
menstrual cycles beyond the natural menopause, this method
is technically available and evidence suggests that it will sub-
stantially prolong the period with menstrual cycles. Alterna-
tively, some womenmay wish to undergo endometrial ablation
to avoid menstrual bleeding, which is one additional medical
intervention that needs consideration. The real beneﬁt of post-
poning menopause by transplanting ovarian tissue still needs
to be proven, but it does represent a physiological solution
to dampen the massive medical legacy of menopause-related
conditions, which will only increase in the coming years.
Thousands of women worldwide have already had ovarian
tissue frozen for fertility preservation due to different ma-
lignancies. For various reasons, a large number of these women
will not have used their tissue by the time they reach meno-
pause, either prematurely or at the expected time of meno-
pause and will have tissue available for continued ovarian
function. Some of them might want to use it for postponing
menopause. They will indeed have this opportunity available
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Figure 1 (A) Postponing menopause by cryopreservation of ovarian tissue. (B) Frozen-thawed human ovarian cortex from a 26-year-
old-woman stained with Neutral Red in situ. All the small red dots represent viable human follicles within the cortical tissue.
(C) Isolated human pre-antral follicles. An enzymatic-mix of Liberase TM, Collagenase IV and DNAse I combined with the Neutral Red
stain was used to digest the ovarian tissue (Kristensen et al., 2011). (D) Isolated human follicles encapsulated in a 0.5% alginate hydrogel
bead (volume = 3 µl).
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without experiencing additional risks and may represent a
group of patients in which initial results can be obtained.
Furthermore, it is now becoming possible to isolate human
pre-antral follicles from the ovarian tissue by various enzy-
matic treatments (Kristensen et al., 2011). Very high numbers
of human resting follicles are located in the cortical tissue,
and in the future it may become possible to isolate them
(Figure 1B,C). Cryopreservation of isolated human pre-
antral follicles is now also available (Camboni et al., 2013),
which implies that a predetermined number of follicles may
be transplanted in small alginate beads just a few microlitres
in size, for instance (Figure 1D). This gives potential for new
methods of even better utilization of the follicular store,
because just a few follicles transplanted to a post-menopausal
woman with high FSH concentrations may be sufﬁcient to
stimulate one or two follicles to the pre-ovulatory sex-
steroid producing stage. When these techniques are further
developed and reﬁned they may represent a source of fol-
licles that could last even longer than pieces of ovarian cortex.
In conclusion, a new technical method for postponing meno-
pause is now available. By cryopreserving ovarian tissue at
a young age the time to natural menopause may be pro-
longed extensively. The advantages include providing natural
circulating concentrations of sex steroids and other sub-
stances for prolonged periods of time; excision of tissue only
slightly advances the age of menopause and does not reduce
fertility. Ovarian tissue may be grafted subcutaneously using
local anaesthesia, for instance, and will only provide hor-
mones and not fertility. However, many questions remain un-
answered: (i) Will there be an increased risk of cancer due
to the grafted tissue? (ii) How long will the tissues actually
last in women who are menopausal? and (iii) Howmany women
will be attracted to postponed menopause, with continued
menstruation?
Although the main goal of ovarian cryopreservation is cur-
rently fertility preservation, transplantation of frozen-
thawed ovarian tissue may serve as a physiological solution
toprevent themassivemedical legacy of osteoporosis andother
menopause-related disorders in the ageing population. The
aim of this commentary is to open up a discussion: is it aworth-
while endeavour to explore this new technical opportunity to
postpone menopause further? In the future, will it be pos-
sible to utilize the enormous loss of human follicles that natu-
rally occur to avoidmenopause for prolonged periods of time?
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